Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Drugs Made In America Acquisition (DMAA) EPS (Weighted Average and Diluted) (2025)

Drugs Made In America Acquisition filings provide 1 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.09 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) changed N/A to -$0.09 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.19 through Dec 2025, changed N/A year-over-year, with the annual reading at $0.19 for FY2025, 733.33% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.09 in Q4 2025 for Drugs Made In America Acquisition, down from $0.07 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.07 in Q2 2025 and bottomed at -$0.09 in Q4 2025.